老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Lakewood-Amedex Biotherapeutics (Direct Listing)
2.09
-0.0800
-3.69%
盤後:
2.02
-0.0680
-3.25%
19:35 EDT
成交量:
5.54萬
成交額:
11.69萬
市值:
495.27萬
市盈率:
-0.20
高:
2.18
開:
2.18
低:
2.08
收:
2.17
52周最高:
98.20
52周最低:
1.66
股本:
236.97萬
流通股本:
141.56萬
量比:
0.05
換手率:
3.91%
股息:
- -
股息率:
- -
每股收益(TTM):
-10.2000
每股收益(LYR):
-8.3987
淨資產收益率:
-402.84%
總資產收益率:
-139.40%
市淨率:
1.14
市盈率(LYR):
-0.25
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足潰瘍二期a階段試驗最終籌備
美股速递
·
07/15
Lakewood-Amedex Biotherapeutics - Nu-3在臨床前研究中展現良好耐受性,高劑量下系統暴露量低
美股速递
·
07/15
Lakewood-Amedex Biotherapeutics公布臨床前安全性數據,支持Nu-3凝膠即將開展的2a期試驗劑量選擇
美股速递
·
07/15
Lakewood-Amedex Biotherapeutics 準備推進 Nu-3 針對感染性糖尿病足潰瘍的二期臨床開發
美股速递
·
07/07
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/LABT"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":2.09,"timestamp":1789588800000,"preClose":2.17,"halted":0,"volume":55405,"hourTrading":{"tag":"盘后","latestPrice":2.022,"preClose":2.09,"latestTime":"19:35 EDT","volume":3595,"amount":7309.9053,"timestamp":1789601753488,"change":-0.068,"changeRate":-0.032536,"amplitude":0.047847},"delay":0,"changeRate":-0.03686635944700464,"floatShares":1415552,"shares":2369700,"eps":-10.199959,"marketStatus":"未開盤","change":-0.08,"latestTime":"09-16 16:00:00 EDT","open":2.18,"high":2.18,"low":2.08,"amount":116926.66767599998,"amplitude":0.046083,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.199959,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":0,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":2.17,"preHourTrading":{"tag":"盘前","latestPrice":2.1395,"preClose":2.17,"latestTime":"09:20 EDT","volume":2120,"amount":4422.260216,"timestamp":1789564810649,"change":-0.0305,"changeRate":-0.014055,"amplitude":0.050691},"postHourTrading":{"tag":"盘后","latestPrice":2.022,"preClose":2.09,"latestTime":"19:35 EDT","volume":3595,"amount":7309.9053,"timestamp":1789601753488,"change":-0.068,"changeRate":-0.032536,"amplitude":0.047847},"volumeRatio":0.048848},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":1415552,"roa":"-139.40%","roe":"-402.84%","lyrEps":-8.39872,"volumeRatio":0.048848,"shares":2369700,"dividePrice":0,"high":2.18,"amplitude":0.046083,"preClose":2.17,"low":2.08,"week52Low":1.66,"pbRate":"1.14","week52High":98.2,"institutionHeld":0,"latestPrice":2.09,"eps":-10.199959,"divideRate":0,"volume":55405,"delay":0,"ttmEps":-10.199959,"open":2.18,"prevYearClose":80,"prevWeekClose":2.22,"prevMonthClose":2.5,"prevQuarterClose":3.14,"fiveDayClose":2.32,"twentyDayClose":2.3,"sixtyDayClose":3.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-09-15","current":-0.204903,"percent":0.877778,"low":-12.282138,"twenty":-2.72924,"median":-0.930704,"eighty":-0.722449,"high":-0.606341,"avg":-2.378201,"sd":3.106358,"marketCap":5023738},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-24","current":-1.03562,"twenty":-3.225364,"median":-2.41344,"eighty":-0.92732,"marketCap":4382030},{"date":"2026-07-31","current":-0.653185,"twenty":-2.937143,"median":-2.34533,"eighty":-0.879262,"marketCap":2763829},{"date":"2026-08-07","current":-0.754716,"twenty":-2.857942,"median":-1.477578,"eighty":-0.80819,"marketCap":3193440},{"date":"2026-08-14","current":-0.78856,"twenty":-2.830251,"median":-1.371504,"eighty":-0.793975,"marketCap":3336643},{"date":"2026-08-21","current":-0.706322,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"marketCap":5189616},{"date":"2026-08-28","current":-0.803079,"twenty":-2.760875,"median":-1.18284,"eighty":-0.754039,"marketCap":5900523},{"date":"2026-09-04","current":-0.612791,"twenty":-2.735567,"median":-1.116845,"eighty":-0.749426,"marketCap":4502407},{"date":"2026-09-11","current":-0.661169,"twenty":-2.730282,"median":-1.03562,"eighty":-0.735555,"marketCap":4857860},{"date":"2026-09-15","current":-0.683746,"twenty":-2.72924,"median":-0.930704,"eighty":-0.722449,"marketCap":5023738}],"updateTime":1789618148337},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1105205621","title":"Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足潰瘍二期a階段試驗最終籌備","url":"https://stock-news.laohu8.com/highlight/detail?id=1105205621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105205621?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 20:04","pubTimestamp":1784117062,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已进入其针对感染性糖尿病足溃疡治疗的二期a阶段临床试验的最终准备阶段。公司正集中资源推进试验流程,标志着其核心疗法开发进入关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064134","title":"Lakewood-Amedex Biotherapeutics - Nu-3在臨床前研究中展現良好耐受性,高劑量下系統暴露量低","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064134","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146064134?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 20:03","pubTimestamp":1784117015,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics(直接上市)宣布,其候选药物Nu-3在近期完成的临床前研究中取得了积极结果。数据显示,即使在较高剂量下,Nu-3也表现出良好的耐受性,且系统暴露水平维持在较低范围。这一发现为该药物的进一步开发提供了重要的安全性依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125245294","title":"Lakewood-Amedex Biotherapeutics公布臨床前安全性數據,支持Nu-3凝膠即將開展的2a期試驗劑量選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=1125245294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125245294?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 20:03","pubTimestamp":1784116990,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司宣布了其Nu-3凝胶的临床前安全性数据。这些关键数据为即将启动的2a期临床试验中的临床剂量选择提供了有力支持。研究结果表明,Nu-3凝胶在所测试的剂量范围内展现出良好的安全性特征,这为后续临床研究的顺利推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150730441","title":"Lakewood-Amedex Biotherapeutics 準備推進 Nu-3 針對感染性糖尿病足潰瘍的二期臨床開發","url":"https://stock-news.laohu8.com/highlight/detail?id=1150730441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150730441?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 20:08","pubTimestamp":1783426135,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 正准备将其候选药物 Nu-3 推进至二期临床开发阶段,该药物旨在治疗感染性糖尿病足溃疡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LABT\",params:#limit:6,delay:false,,,undefined,":[]}}